TheraRadar
Clinical-Stage Companies / Immunovant Sciences

Immunovant Sciences

Pre-Approval PRO BETA
19
Total Trials
5
Phase 3
14
Phase 2
9
Recruiting
197
Score

Pipeline by Phase

Phase 3
5
Phase 2
14
Phase 1

Therapeutic Focus

Chronic Inflammatory Demyelinating Polyneuropathy Graves' Disease Thyroid Eye Disease Generalized Myasthenia Gravis Primary Sjögren's Syndrome

Clinical Trials (19)

NCT07039916 Phase 3 RECRUITING

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Started: 5/27/2025

NCT05517447 Phase 3 TERMINATED

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Started: 11/6/2022

NCT05524571 Phase 3 COMPLETED

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Started: 1/5/2023

NCT05403541 Phase 3 ACTIVE NOT RECRUITING

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Started: 6/27/2022

NCT05517421 Phase 3 COMPLETED

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Started: 11/23/2022

NCT07032662 Phase 2 RECRUITING

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Started: 3/18/2025

NCT06979531 Phase 2 RECRUITING

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Started: 6/30/2025

NCT07018323 Phase 2 RECRUITING

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Started: 6/19/2025

NCT06727604 Phase 2 RECRUITING

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Started: 12/17/2024

NCT07286006 Phase 2 ENROLLING BY INVITATION

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

Started: 1/26/2026

NCT06754462 Phase 2 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

Started: 1/10/2025

NCT06980805 Phase 2 ACTIVE NOT RECRUITING

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Started: 2/19/2025

NCT05907668 Phase 2 COMPLETED

A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Started: 5/15/2023

NCT07188844 Phase 2 ENROLLING BY INVITATION

An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Started: 8/28/2025

NCT05581199 Phase 2 ACTIVE NOT RECRUITING

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Started: 12/15/2022

NCT03863080 Phase 2 COMPLETED

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Started: 5/21/2019

NCT03938545 Phase 2 TERMINATED

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Started: 7/23/2019

NCT04253236 Phase 2 TERMINATED

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

Started: 8/11/2020

NCT03922321 Phase 2 COMPLETED

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

Started: 4/22/2019

Drug Candidates

Imeroprubart IMVT-1402 Batoclimab Batoclimab 680 mg SC weekly Batoclimab 340 mg SC weekly Batoclimab 340 mg SC bi-weekly IMVT-1401 (batoclimab) Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly RVT-1401 RVT-1401 (Administered via subcutaneous injection)
Activity Status: Active
Last Trial Started: 1/26/2026
Last Trial Ended: 4/2/2026
Trials (12 months): 2
Completed Trials: 5
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.